Literature DB >> 15166437

Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3.

Hong Yu1, Lorne A Babiuk1, Sylvia van Drunen Littel-van den Hurk1.   

Abstract

Cell-mediated immune responses to hepatitis C virus (HCV) proteins play a key role in recovery from infection. The NS3 protein of HCV is of special interest, since it is one of the most conserved proteins and NS3-specific immune responses are stronger and more frequently observed in patients resolving the infection than in chronically infected patients. Since these characteristics make NS3 an attractive vaccine candidate, the objective of this study was to optimize NS3-specific immune responses. Results from this group first demonstrated that a plasmid enriched with 24 CpG motifs (pBISIA24-NS3) tends to induce the strongest and most consistent Th1-biased immune response. Subsequently, it was shown that NS3 formulated with CpG oligodeoxynucleotide and Quil A (rNS3+CpG+Quil A) adjuvants induces a balanced immune response in mice, whereas rNS3 combined with either CpG or Quil A elicits a Th2-biased response. To further enhance NS3-specific cell-mediated immune responses, a vaccination regime consisting of priming with pBISIA24-NS3, followed by boosting with rNS3+CpG+Quil A, was explored in mice and pigs. When compared to immunization with rNS3+CpG+Quil A, this regime shifted the immune response to a Th1-type response and, accordingly, enhanced MHC I-restricted killing by cytotoxic T lymphocytes in mice. Although immunization with pBISIA24-NS3 also induced a Th1-biased response, including cytotoxicity in the mice, the humoral response was significantly lower than that induced by the DNA prime-protein boost regime. These results demonstrate the advantage of a DNA prime-protein boost approach in inducing a strong NS3-specific cell-mediated, as well as humoral, immune response, in both inbred laboratory and outbred large animal species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166437     DOI: 10.1099/vir.0.79821-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

Review 1.  Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments.

Authors:  Philip Wintermeyer; Jack R Wands
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

2.  Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models.

Authors:  Yi-Ping Li; Hye-Na Kang; Lorne-A Babiuk; Qiang Liu
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

3.  Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine.

Authors:  Ning Luan; Han Cao; Yunfei Wang; Kangyang Lin; Cunbao Liu
Journal:  Pharmaceutics       Date:  2022-04-30       Impact factor: 6.525

4.  Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.

Authors:  Bo Jin; Richard Y Wang; Qi Qiu; Fuminaka Sugauchi; Teresa Grandinetti; Harvey J Alter; J Wai-Kuo Shih
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

5.  Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus.

Authors:  Jin-Won Youn; Yu-Wen Hu; Nancy Tricoche; Wolfram Pfahler; Mohamed Tarek Shata; Marlene Dreux; François-Loic Cosset; Antonella Folgori; Dong-Hun Lee; Betsy Brotman; Alfred M Prince
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

6.  Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants.

Authors:  Qi Qiu; Richard Yuan-Hu Wang; Xuanmao Jiao; Bo Jin; Fuminaka Sugauchi; Teresa Grandinetti; Harvey J Alter; J Wai-Kuo Shih
Journal:  Vaccine       Date:  2008-09-02       Impact factor: 3.641

7.  Enhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen.

Authors:  Na Zhan; Bing S Xiu; Guo H Wang; Kun Chen; Guan Z Bai; Xiao G Song; Cui X Zhu; Zhen H Dai; Xi Q Yang; He Q Zhang
Journal:  Virol J       Date:  2011-11-04       Impact factor: 4.099

8.  Hepatitis C virus DNA vaccines: a systematic review.

Authors:  Ali Shayeghpour; Roya Kianfar; Parastoo Hosseini; Mehdi Ajorloo; Sepehr Aghajanian; Mojtaba Hedayat Yaghoobi; Tayebeh Hashempour; Sayed-Hamidreza Mozhgani
Journal:  Virol J       Date:  2021-12-13       Impact factor: 4.099

Review 9.  CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.198

10.  G2 Dendrimer as a Carrier Can Enhance Immune Responses Against HCV-NS3 Protein in BALB/c Mice.

Authors:  Foozieh Javadi; Pooneh Rahimi; Mohammad Hossien Modarresi; Azam Bolhassani; Mehdi Shafiee Ardestani; Seyed Mehdi Sadat
Journal:  Avicenna J Med Biotechnol       Date:  2019 Oct-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.